Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers with very few available treatments. For many decades, gemcitabine was the only treatment for patients with PDAC. A recent attempt to improve patient survival by combining this chemotherapy with FOLFIRINOX and na...
| الحاوية / القاعدة: | Frontiers in Immunology |
|---|---|
| المؤلفون الرئيسيون: | , , , , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
Frontiers Media S.A.
2018-05-01
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://journal.frontiersin.org/article/10.3389/fimmu.2018.01044/full |
